BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

The recent failure of IFNβ in WHO’s master protocol trial for COVID-19 notwithstanding, there are plenty of reasons to suspect that interferons should be effective treatments for the infection. An analysis...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
BioCentury | Sep 5, 2020
Deals

Deal with AbbVie, PIPE triples I-Mab’s cash, positions biotech to be among China’s CD47 leaders

Immuno-oncology company I-Mab nearly tripled its cash position on Friday, adding more than $600 million to its coffers through a CD47 licensing deal with AbbVie and a PIPE financing led by Hillhouse Capital. The deal...
BioCentury | Aug 12, 2020
Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

Bayer’s $425 million takeout of menopause play KaNDy sends a signal to investors that women’s health can deliver a return. Private companies working in the space have long struggled to raise venture money. “Women’s health,...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells. In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay...
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

Novo Ventures has led a $55 million series B round for NodThera, a trans-Atlantic biotech operating in an area ripe for takeouts -- the inflammasome. The biotech's lead program targets NLRP3, a target explored by...
BioCentury | May 27, 2020
Top Story

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

Gilead’s partnership with Arcus gives it access to a pipeline ripe for immuno-oncology combinations around closely watched targets, such as TIGIT. But the agreement doesn’t mirror Gilead’s last deal, in which partnering negotiations with Forty...
BioCentury | May 2, 2020
Translation in Brief

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

Small molecule CD73 inhibitor for cancer A small molecule CD73 inhibitor from ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) has shown significant antitumor activity in vivo . ORIC-533 is slated for an IND submission in 1H21. CD73, which is...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...
BioCentury | Apr 16, 2020
Deals

Arcus mum on report of Gilead’s approach

Shares of oncology company Arcus rose sharply Thursday as the company remained quiet about a published report that said Gilead had approached it about a partnership or equity investment. Arcus Biosciences Inc. (NYSE:RCUS) gained $14.01...
Items per page:
1 - 10 of 410